Chuangjian Medical is a biopharmaceutical research and development company with the mission of developing recombinant collagen biomaterials, and is committed to the R&D and production of recombinant collagen-based biomaterials. Recently, Chuangjian Medical completed the first round of financing of nearly 200 million yuan, led by Shiseido Ziyue Fund, and joined by Huafang Capital, CDH Baifu, and Huali Medicine. This round of financing will support Chuangjian Medical to continue to expand its investment in technological innovation and product research and development, and bring more abundant core technologies and products to the recombinant collagen biomaterial market.
This article is reproduced from: https://www.itjuzi.com/investevent/13470650
This site is for inclusion only, and the copyright belongs to the original author.